EP06.03-05 EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy
Journal of Thoracic Oncology(2023)
摘要
The third most common Epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancer (NSCLC) is the exon 20 insertion mutations (E20ins), comprising 1-10% of total EGFR mutations. The Human Genome Variation Society (HGVS) provides nomenclature for accurate and consistent communication, helping to avoid confusion caused by inconsistent or ambiguous naming conventions. Despite this, several publications have described EGFR E20ins confusingly, highlighting the need for adequate description using HGVS nomenclature.
更多查看译文
关键词
egfr exon,insertion mutations,nsclc,accurate naming conventions
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要